Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruboxistaurin - Chromaderm/Recursion Pharmaceuticals

Drug Profile

Ruboxistaurin - Chromaderm/Recursion Pharmaceuticals

Alternative Names: Arxxant; DBI-102; LY-333531; REC 3599; SM 030

Latest Information Update: 03 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer DermBiont; Eli Lilly and Company; Recursion Pharmaceuticals; Takeda
  • Class Eye disorder therapies; Heart failure therapies; Indoles; Maleimides; Skin disorder therapies
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Protein kinase C beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperpigmentation; Melanosis; Skin disorders
  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; GM2 gangliosidoses; Heart failure

Most Recent Events

  • 31 Dec 2022 Discontinued - Phase-I for GM2 gangliosidoses in USA (PO)
  • 18 Aug 2022 Phase-II clinical trials in Hyperpigmentation in El Salvador (Topical) (NCT05511948)
  • 07 Mar 2022 Phase-I clinical trials in GM2 gangliosidoses in USA (PO) before March 2022 (Recursion Pharmaceuticals' pipeline, March 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top